Chinese Biotech Firm Secures Pfizer Deal Despite Trade Tensions

Chinese biotech firm secures Pfizer deal despite trade tensions

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s 3SBio.

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to BioNTech, Merck & Co. and Summit Therapeutics in a scorching-hot area of immuno-oncology. Interest in PD-1/L1xVEGF bispecifics has been high since Summit and Akeso’s ivonescimab […] The post Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot …

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

Pfizer is set to enter the heated VEGF bispecific arena. Much like its peers, the New York drug giant is doing so by going to China in the battle for one of oncology's hottest classes ...